A possible "universal" cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue
- PMID: 17629418
- DOI: 10.1016/j.mehy.2007.04.040
A possible "universal" cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue
Abstract
Since an ongoing interaction between a potential cancer cell and its microenvironment is a necessary requirement for their co-evolution towards a malignant disease state, a future success of cancer prevention will depend on how effectively a vaccination strategy simultaneously acts on emerging pretumor cells as well as on its microenvironment. Based on the assumption and theory that a placental vaccine could induce humoral and cell-mediated immune response against both the embryo-like antigens and angiogenic factors that are common to placental and cancer cells, this vaccination would create an immunological state in normal healthy individuals which would result in rejection of foreign nascent transforming cells, or cancer initiating cells (so called cancer stem cells). Immunoplacental Vaccine (Human placenta whole cell lysates) prepared upon Filatov's method, consisting of heat shock proteins and associated placental peptide complexes-version of homologous non-mutated proteins that are found on different kinds of epithelial cancer cells, when intradermal coinjected with an adjuvant, i.e. BCG-Vaccine, in normal healthy individuals, may function as a multi-epitope vaccine; the body recognizes the placental antigens of this vaccine as foreign, and thus stimulates a cross-reactive humoral and cell-mediated immune response targeting cancer tumor-associated antigens (TAA), as well as proteins that aid in cancer development. Also, by eliciting of critical cytokines at the vaccination site may result in cytokine-network balancing and in promoting Th1 cell-mediated immunity in the local microenvironment of preneoplastic to neoplastic transformation. Thus, this vaccination approach, by fine-tuning T-cell repertoire, T-cell regulation and cytokine-network balancing in the local microenvironment of preneoplastic to neoplastic transformation, acts on both "abnormal cells" and their "abnormal microenvironment", in which abnormal clones develop.
Similar articles
-
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.Cancer Res. 2008 Feb 1;68(3):861-9. doi: 10.1158/0008-5472.CAN-07-0445. Cancer Res. 2008. PMID: 18245488
-
The relevance of cytokines for development of protective immunity and rational design of vaccines.Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):195-207. doi: 10.1016/j.cytogfr.2007.01.016. Epub 2007 Mar 7. Cytokine Growth Factor Rev. 2007. PMID: 17347024 Review.
-
Therapeutic cancer vaccines: using unique antigens.Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14653-6. doi: 10.1073/pnas.0404839101. Epub 2004 Aug 5. Proc Natl Acad Sci U S A. 2004. PMID: 15297620 Free PMC article. Review.
-
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
-
Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.Vaccine. 2009 Aug 27;27(39):5411-8. doi: 10.1016/j.vaccine.2009.06.089. Epub 2009 Jul 17. Vaccine. 2009. PMID: 19616501
Cited by
-
Cancer Is Associated with the Emergence of Placenta-Reactive Autoantibodies.Biomedicines. 2023 Jan 23;11(2):316. doi: 10.3390/biomedicines11020316. Biomedicines. 2023. PMID: 36830854 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources